OraPharma, Inc., a specialty pharmaceutical company founded in 1996 with an initial focus on the emerging field of oral health care, discovers, develops and commercializes therapeutics for oral health. OraPharma's initial product, ARESTIN®, represents a promising therapeutic advance for the adjunct treatment of periodontal disease. ARESTIN® is the first locally administered time-released antibiotic encapsulated in microspheres that effectively kills the germs that cause periodontal disease or periodontitis, a disease that affects more than 50 million people in the U.S.